Table 2.
Disposition of patients included in the mITT analysis7
| Disposition | Micafungin (N=58) |
Posaconazole (N=55) |
||
|---|---|---|---|---|
| N (%) | N (%) | |||
| Did not complete prophylaxis | 24 (41.4) | 21 (38.2) | ||
| Clinical failure | 20 (34.5) | 29 (52.7) | ||
| Other8 | 4 (6.9) | 5 (9.1) | ||
| Did not complete study9 | 7 (12.1) | 2 (3.6) | ||
| Median (IQR) |
Median (IQR) | |||
| Days on prophylaxis | 16 (12-20) | 13 (6-16) | ||
| N (%) | N (%) | |||
| Reasons for failure | ||||
| Antifungal therapy | 19 (95%) | 12 (41.4) | ||
| Possible IFI | 6 | 3 | ||
| Probable IFI | 1 | 0 | ||
| Persistent fever | 3 | 3 | ||
| Abnormal CT chest10 | 8 | 6 | ||
| Other11 | 1 | 0 | ||
| Gastrointestinal intolerance | 0 | 13 (44.8) | ||
| TEAE | 0 | 4 (13.8) | ||
| Death | 1 (5%) | 0 (0) |
7
Abbreviations: mITT = modified intention-to-treat; IFI = invasive fungal infection; CT = computed tomography; TEAE = treatment-emergent adverse event.
8
These did not complete prophylaxis but did not meet criteria for clinical failure.
9
12 weeks from first dose of antifungal prophylaxis.
10
New findings on chest CT not meeting EORTC (European Organization for Research and Treatment of Cancer) criteria for IFI.
11
Throat fungal culture with Aspergillus spp., not meeting EORTC criteria for IFI.